{"protocolSection":{"identificationModule":{"nctId":"NCT01769391","orgStudyIdInfo":{"id":"14790"},"secondaryIdInfos":[{"id":"I4X-MC-JFCL","type":"OTHER","domain":"Eli Lilly and Company"},{"id":"2012-003214-13","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Eli Lilly and Company","class":"INDUSTRY"},"briefTitle":"A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer","officialTitle":"A Randomized, Multicenter, Open-Label, Phase 2 Study of Paclitaxel-Carboplatin Chemotherapy Plus Necitumumab (IMC-11F8) Versus Paclitaxel-Carboplatin Chemotherapy Alone in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)"},"statusModule":{"statusVerifiedDate":"2019-09","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2013-01"},"primaryCompletionDateStruct":{"date":"2015-04","type":"ACTUAL"},"completionDateStruct":{"date":"2017-07","type":"ACTUAL"},"studyFirstSubmitDate":"2013-01-14","studyFirstSubmitQcDate":"2013-01-14","studyFirstPostDateStruct":{"date":"2013-01-16","type":"ESTIMATED"},"resultsFirstSubmitDate":"2016-03-31","resultsFirstSubmitQcDate":"2016-03-31","resultsFirstPostDateStruct":{"date":"2016-05-05","type":"ESTIMATED"},"dispFirstSubmitDate":"2015-05-08","dispFirstSubmitQcDate":"2015-05-08","dispFirstPostDateStruct":{"date":"2015-05-25","type":"ESTIMATED"},"lastUpdateSubmitDate":"2019-09-05","lastUpdatePostDateStruct":{"date":"2019-09-20","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Eli Lilly and Company","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"The main purpose of this study is to evaluate if necitumumab added to standard chemotherapy of paclitaxel and carboplatin is more effective to treat cancer than the standard chemotherapy of paclitaxel and carboplatin alone."},"conditionsModule":{"conditions":["Squamous Non Small Cell Lung Cancer"],"keywords":["NSCLC"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":167,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Necitumumab +Paclitaxel+Carboplatin","type":"EXPERIMENTAL","description":"Necitumumab 800 milligram (mg) administered intravenously (IV) on Days 1 and 8 of every 3 week cycle.\n\nPaclitaxel 200 milligram per square meter (mg/m²) administered IV on Day 1 of every 3 week cycle.\n\nCarboplatin Area Under the Curve (AUC)6 (mg•min/mL) administered IV on Day 1 of every 3 week cycle.\n\nThe combination of paclitaxel-carboplatin and necitumumab may continue for a maximum of 6 cycles. Necitumumab may continue until Progressive Disease (PD), toxicity requiring cessation, protocol noncompliance, or withdrawal of consent.","interventionNames":["Drug: Necitumumab","Drug: Paclitaxel","Drug: Carboplatin"]},{"label":"Paclitaxel + Carboplatin","type":"ACTIVE_COMPARATOR","description":"Paclitaxel 200 mg/m² administered IV on Day 1 of every 3 week cycle. Carboplatin AUC=6 administered IV on Day 1 of every 3 week cycle. The combination of paclitaxel-carboplatin may continue for a maximum of 6 cycles. After completion of chemotherapy, participants will be followed until radiographic documentation of PD.","interventionNames":["Drug: Paclitaxel","Drug: Carboplatin"]}],"interventions":[{"type":"DRUG","name":"Necitumumab","description":"Administered IV","armGroupLabels":["Necitumumab +Paclitaxel+Carboplatin"],"otherNames":["LY3012211","IMC-11F8"]},{"type":"DRUG","name":"Paclitaxel","description":"Administered IV","armGroupLabels":["Necitumumab +Paclitaxel+Carboplatin","Paclitaxel + Carboplatin"]},{"type":"DRUG","name":"Carboplatin","description":"Administered IV","armGroupLabels":["Necitumumab +Paclitaxel+Carboplatin","Paclitaxel + Carboplatin"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response (CR) or Partial Response (PR) (Objective Response Rates [ORR])","description":"The denominator of ORR (Objective Response Rate) includes each participant enrolled who received any amount of study drug (necitumumab, gemcitabine, and/or cisplatin), and who had a complete radiographic assessment at baseline and at least one complete radiographic assessment post-baseline. The numerator includes those participants counted in the denominator with a confirmed best overall tumor response of partial or complete response (Complete Response (CR): disappearance of all non-nodal target lesions, with the short axes of any target lymph nodes reduced to \\<10 millimeters (mm). Partial Response (PR): at least a 30% decrease in the sum of the diameters of target lesions (including the short axes of any target lymph nodes), taking as reference the baseline sum diameter.) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.","timeFrame":"Baseline to Disease Progression or Death (Up to 24 Months)"}],"secondaryOutcomes":[{"measure":"Overall Survival (OS)","description":"OS defined as the time from the date of randomization to the date of death from any cause. For participants not known to have died as of the data cut-off date, OS was censored at the last contact date (last contact for participants in post-discontinuation = last known alive date in mortality status).","timeFrame":"Randomization to Date of Death (Up to 24 Months)"},{"measure":"Pharmacokinetics (PK): Maximum Concentration (Cmax) of Necitumumab","timeFrame":"Pre-infusion Cycle 1, Day 1; Cycle 3, Day 1; Cycle 5; Day 1 (within 2 hours prior to beginning of infusion)"},{"measure":"Percentage of Participants With Anti Necitumumab Antibodies","timeFrame":"Baseline to End of Cycle 6"},{"measure":"Progression-Free Survival","description":"Progression-Free Survival (PFS) is defined as the time from randomization until the first radiographically documented progressive disease (PD) or death from any cause. PD defined by Response Evaluation Criteria in Solid Tumors Criteria (RECIST version 1.1) as at least a 20% increase in the sum of the diameters of target lesions,taking as reference the smallest sum on study (including the baseline sum if that is the smallest). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression. For participants not known to have died as of the data cut-off date and who do not have objective PD, PFS will be censored at the date of the last complete radiographic assessment.","timeFrame":"Randomization to Progressive Disease or Death (Up to 24 Months)"},{"measure":"Percentage of Participants Who Achieve Best Overall Disease Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD) (Disease Control Rate [DCR])","description":"Defined using the same denominator as defined in ORR. Among participants counted in the denominator, the numerator counts those with a confirmed best tumor response of SD, PR, or CR per RECIST 1.1. (SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD; PR at least 30% decrease in the sum of diameter of target lesions; CR: disappearance of all target lesions).","timeFrame":"Baseline to Progressive Disease and/or Death (Estimated up to 24 Months)"},{"measure":"Percent Change in Tumor Size (CTS)","description":"CTS is defined as maximum percent change from baseline in the sum of target lesions.","timeFrame":"Baseline to Progressive Disease or Death (Up to 24 Months)"},{"measure":"Pharmacokinetics (PK): Minimum Concentration (Cmin) of Necitumumab","timeFrame":"Cycle 1, Day 8 ; Cycle 2, Day 1; Cycle 3, Day 1;Cycle 4, Day1;Cycle 5, Day 1; Cycle 6, Day 1 (within 2 hours prior to beginning of infusion)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologically or cytologically confirmed squamous NSCLC\n* Stage IV disease at time of study entry based on American Joint Committee on Cancer (AJCC) 7th edition\n* Measurable disease at time of study entry as defined by Response Evaluation Criteria in Solid Tumors, (RECIST) Version 1.1\n* Archived or recent tumor tissue (minimum of 5 unstained tissue slides or a paraffin-embedded tissue block) available for analysis of epidermal growth factor receptor (EGFR) protein expression by immunohistochemistry (IHC) and other biomarker assessments\n\nExclusion Criteria:\n\n* Nonsquamous NSCLC\n* Prior anticancer therapy with monoclonal antibodies, signal transduction inhibitors, or any therapies targeting the EGFR, vascular endothelial growth factor (VEGF), or VEGF receptor\n* Previous chemotherapy for NSCLC\n* Major surgery or received any investigational therapy in the 4 weeks prior to randomization\n* Chest irradiation within 12 weeks prior to randomization (except palliative irradiation of bone lesions, which is allowed)\n* Brain metastases that are symptomatic or require ongoing treatment with steroids or anticonvulsants (Participants who have undergone previous radiotherapy for brain metastases, who are now nonsymptomatic and no longer require treatment with steroids or anticonvulsants, are eligible)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)","affiliation":"Eli Lilly and Company","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Jonesboro","state":"Arkansas","zip":"72401","country":"United States","geoPoint":{"lat":35.8423,"lon":-90.70428}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Los Angeles","state":"California","zip":"90048","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Sacramento","state":"California","zip":"95816","country":"United States","geoPoint":{"lat":38.58157,"lon":-121.4944}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Colorado Springs","state":"Colorado","zip":"80907","country":"United States","geoPoint":{"lat":38.83388,"lon":-104.82136}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Fleming Island","state":"Florida","zip":"32003","country":"United States","geoPoint":{"lat":30.0933,"lon":-81.71898}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Fort Myers","state":"Florida","zip":"33916","country":"United States","geoPoint":{"lat":26.62168,"lon":-81.84059}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Miami Beach","state":"Florida","zip":"33140","country":"United States","geoPoint":{"lat":25.79065,"lon":-80.13005}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Port Saint Lucie","state":"Florida","zip":"34952","country":"United States","geoPoint":{"lat":27.29393,"lon":-80.35033}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"St. Petersburg","state":"Florida","zip":"33705","country":"United States","geoPoint":{"lat":27.77086,"lon":-82.67927}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Macon","state":"Georgia","zip":"31201","country":"United States","geoPoint":{"lat":32.84069,"lon":-83.6324}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Marietta","state":"Georgia","zip":"30060","country":"United States","geoPoint":{"lat":33.9526,"lon":-84.54993}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Savannah","state":"Georgia","zip":"31404","country":"United States","geoPoint":{"lat":32.08354,"lon":-81.09983}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Valdosta","state":"Georgia","zip":"31602","country":"United States","geoPoint":{"lat":30.83334,"lon":-83.28032}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Wichita","state":"Kansas","zip":"67214","country":"United States","geoPoint":{"lat":37.69224,"lon":-97.33754}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Louisville","state":"Kentucky","zip":"40202","country":"United States","geoPoint":{"lat":38.25424,"lon":-85.75941}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Kalamazoo","state":"Michigan","zip":"49007","country":"United States","geoPoint":{"lat":42.29171,"lon":-85.58723}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Lansing","state":"Michigan","zip":"48910","country":"United States","geoPoint":{"lat":42.73253,"lon":-84.55553}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Woodbury","state":"Minnesota","zip":"55125","country":"United States","geoPoint":{"lat":44.92386,"lon":-92.95938}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Billings","state":"Montana","zip":"59101","country":"United States","geoPoint":{"lat":45.78329,"lon":-108.50069}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Lincoln","state":"Nebraska","zip":"68510","country":"United States","geoPoint":{"lat":40.8,"lon":-96.66696}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Cherry Hill","state":"New Jersey","zip":"08003","country":"United States","geoPoint":{"lat":39.93484,"lon":-75.03073}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Hackensack","state":"New Jersey","zip":"07601","country":"United States","geoPoint":{"lat":40.88593,"lon":-74.04347}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Latham","state":"New York","zip":"12110","country":"United States","geoPoint":{"lat":42.74702,"lon":-73.75901}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Cincinnati","state":"Ohio","zip":"45242","country":"United States","geoPoint":{"lat":39.12711,"lon":-84.51439}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Eugene","state":"Oregon","zip":"97401","country":"United States","geoPoint":{"lat":44.05207,"lon":-123.08675}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Charleston","state":"South Carolina","zip":"29425","country":"United States","geoPoint":{"lat":32.77632,"lon":-79.93275}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Columbia","state":"South Carolina","zip":"29210","country":"United States","geoPoint":{"lat":34.00071,"lon":-81.03481}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Chattanooga","state":"Tennessee","zip":"37404","country":"United States","geoPoint":{"lat":35.04563,"lon":-85.30968}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Memphis","state":"Tennessee","zip":"38120","country":"United States","geoPoint":{"lat":35.14953,"lon":-90.04898}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Nashville","state":"Tennessee","zip":"37203","country":"United States","geoPoint":{"lat":36.16589,"lon":-86.78444}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Fort Worth","state":"Texas","zip":"76104","country":"United States","geoPoint":{"lat":32.72541,"lon":-97.32085}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"The Woodlands","state":"Texas","zip":"77380","country":"United States","geoPoint":{"lat":30.15799,"lon":-95.48938}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Richmond","state":"Virginia","zip":"23230","country":"United States","geoPoint":{"lat":37.55376,"lon":-77.46026}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Großhansdorf","zip":"22927","country":"Germany","geoPoint":{"lat":53.66528,"lon":10.28552}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Heidelberg","zip":"69126","country":"Germany","geoPoint":{"lat":49.40768,"lon":8.69079}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Immenhausen","zip":"34376","country":"Germany","geoPoint":{"lat":51.42763,"lon":9.48017}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Münster","zip":"48149","country":"Germany","geoPoint":{"lat":51.96236,"lon":7.62571}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Chihuahua City","zip":"31000","country":"Mexico","geoPoint":{"lat":28.63528,"lon":-106.08889}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"León","zip":"37000","country":"Mexico","geoPoint":{"lat":25.60187,"lon":-103.47698}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Mexico City","zip":"6700","country":"Mexico","geoPoint":{"lat":19.42847,"lon":-99.12766}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Monterrey","zip":"64000","country":"Mexico","geoPoint":{"lat":25.68435,"lon":-100.31721}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Głuchołazy","zip":"48-340","country":"Poland","geoPoint":{"lat":50.31505,"lon":17.38355}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Olsztyn","zip":"10-357","country":"Poland","geoPoint":{"lat":53.78376,"lon":20.49272}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Otwock","zip":"05-400","country":"Poland","geoPoint":{"lat":52.10577,"lon":21.26129}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Poznan","zip":"60-693","country":"Poland","geoPoint":{"lat":52.40692,"lon":16.92993}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Radom","zip":"26-617","country":"Poland","geoPoint":{"lat":51.40253,"lon":21.14714}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Warsaw","zip":"02-781","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Saint Petersburg","zip":"194291","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Incheon","zip":"405-760","country":"South Korea","geoPoint":{"lat":37.45646,"lon":126.70515}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Seoul","zip":"135-710","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Ulsan","zip":"682-714","country":"South Korea","geoPoint":{"lat":35.53722,"lon":129.31667}}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.","infoTypes":["STUDY_PROTOCOL","SAP","CSR"],"timeFrame":"Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.","accessCriteria":"A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.","url":"https://vivli.org/"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"A completer is defined as having a complete radiographic assessment at baseline and at least one complete post-baseline radiographic assessment of CR, PR , SD or PD.","groups":[{"id":"FG000","title":"Necitumumab +Paclitaxel+Carboplatin","description":"Necitumumab 800 milligram (mg) administered intravenously (IV) on Days 1 and 8 of every 3 week cycle.\n\nPaclitaxel 200 mg per square meter (mg/m²) administered IV on Day 1 of every 3 week cycle.\n\nCarboplatin AUC6 administered IV on Day 1 of every 3 week cycle."},{"id":"FG001","title":"Paclitaxel + Carboplatin","description":"Paclitaxel 200 mg/m² administered IV on Day 1 of every 3 week cycle. Carboplatin AUC6 administered IV on Day 1 of every 3 week cycle. The combination of paclitaxel-carboplatin may continue for a maximum of 6 cycles."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"110"},{"groupId":"FG001","numSubjects":"57"}]},{"type":"Received at Least One Dose of Study Drug","achievements":[{"groupId":"FG000","numSubjects":"106"},{"groupId":"FG001","numSubjects":"55"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"93"},{"groupId":"FG001","numSubjects":"48"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"17"},{"groupId":"FG001","numSubjects":"9"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"3"}]},{"type":"Progressive Disease","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"3"}]},{"type":"Investigator Decision","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Necitumumab +Paclitaxel+Carboplatin","description":"Necitumumab 800 milligram (mg) administered intravenously (IV) on Days 1 and 8 of every 3 week cycle.\n\nPaclitaxel 200 milligram per square meter (mg/m\\^2) administered IV on Day 1 of every 3 week cycle.\n\nCarboplatin AUC6 administered IV on Day 1 of every 3 week cycle."},{"id":"BG001","title":"Paclitaxel + Carboplatin","description":"Paclitaxel 200 mg/m² administered IV on Day 1 of every 3 week cycle. Carboplatin AUC6 administered IV on Day 1 of every 3 week cycle. The combination of paclitaxel-carboplatin may continue for a maximum of 6 cycles."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"110"},{"groupId":"BG001","value":"57"},{"groupId":"BG002","value":"167"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"65.5","spread":"9.36"},{"groupId":"BG001","value":"64.7","spread":"8.27"},{"groupId":"BG002","value":"65.3","spread":"8.98"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"36"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"87"},{"groupId":"BG001","value":"44"},{"groupId":"BG002","value":"131"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"7"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"105"},{"groupId":"BG001","value":"53"},{"groupId":"BG002","value":"158"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"2"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"16"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"5"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"97"},{"groupId":"BG001","value":"47"},{"groupId":"BG002","value":"144"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Region of Enrollment","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"title":"Russia","categories":[{"measurements":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"40"}]}]},{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"53"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"78"}]}]},{"title":"Poland","categories":[{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"19"}]}]},{"title":"South Korea","categories":[{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"16"}]}]},{"title":"Mexico","categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"6"}]}]},{"title":"Germany","categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"8"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response (CR) or Partial Response (PR) (Objective Response Rates [ORR])","description":"The denominator of ORR (Objective Response Rate) includes each participant enrolled who received any amount of study drug (necitumumab, gemcitabine, and/or cisplatin), and who had a complete radiographic assessment at baseline and at least one complete radiographic assessment post-baseline. The numerator includes those participants counted in the denominator with a confirmed best overall tumor response of partial or complete response (Complete Response (CR): disappearance of all non-nodal target lesions, with the short axes of any target lymph nodes reduced to \\<10 millimeters (mm). Partial Response (PR): at least a 30% decrease in the sum of the diameters of target lesions (including the short axes of any target lymph nodes), taking as reference the baseline sum diameter.) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.","populationDescription":"All randomized participants that received at least 1 dose of study drug, who had a complete radiographic assessment at baseline and at least 1 complete radiographic assessment post-baseline.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Baseline to Disease Progression or Death (Up to 24 Months)","groups":[{"id":"OG000","title":"Necitumumab +Paclitaxel+Carboplatin","description":"Necitumumab 800 milligram (mg) administered intravenously (IV) on Days 1 and 8 of every 3 week cycle.\n\nPaclitaxel 200 milligram per square meter (mg/m²) administered IV on Day 1 of every 3 week cycle.\n\nCarboplatin Area Under the Curve (AUC)6 (mg•min/mL) administered IV on Day 1 of every 3 week cycle."},{"id":"OG001","title":"Paclitaxel + Carboplatin","description":"Paclitaxel 200 mg/m² administered IV on Day 1 of every 3 week cycle. Carboplatin AUC6 administered IV on Day 1 of every 3 week cycle. The combination of paclitaxel-carboplatin may continue for a maximum of 6 cycles."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"50"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.9","lowerLimit":"38.5","upperLimit":"59.5"},{"groupId":"OG001","value":"40.0","lowerLimit":"26.4","upperLimit":"54.8"}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"OS defined as the time from the date of randomization to the date of death from any cause. For participants not known to have died as of the data cut-off date, OS was censored at the last contact date (last contact for participants in post-discontinuation = last known alive date in mortality status).","populationDescription":"All randomized participants; (49 and 19 censored participants in Paclitaxel + Carboplatin + Necitumumab and Paclitaxel + Carboplatin Arms, respectively.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Randomization to Date of Death (Up to 24 Months)","groups":[{"id":"OG000","title":"Necitumumab +Paclitaxel+Carboplatin","description":"Necitumumab 800 milligram (mg) administered intravenously (IV) on Days 1 and 8 of every 3 week cycle.\n\nPaclitaxel 200 milligram per square meter (mg/m²) administered IV on Day 1 of every 3 week cycle.\n\nCarboplatin Area Under the Curve (AUC)6 (mg•min/mL) administered IV on Day 1 of every 3 week cycle."},{"id":"OG001","title":"Paclitaxel + Carboplatin","description":"Paclitaxel 200 mg/m² administered IV on Day 1 of every 3 week cycle. Carboplatin AUC=6 administered IV on Day 1 of every 3 week cycle. The combination of paclitaxel-carboplatin may continue for a maximum of 6 cycles."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"110"},{"groupId":"OG001","value":"57"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.2","lowerLimit":"9.7","upperLimit":"15.9"},{"groupId":"OG001","value":"11.2","lowerLimit":"8.2","upperLimit":"12.7"}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetics (PK): Maximum Concentration (Cmax) of Necitumumab","populationDescription":"All participants who received at least one dose of necitumumab and had evaluable PK data.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"microgram/milliliter (μg/mL)","timeFrame":"Pre-infusion Cycle 1, Day 1; Cycle 3, Day 1; Cycle 5; Day 1 (within 2 hours prior to beginning of infusion)","groups":[{"id":"OG000","title":"Necitumumab +Paclitaxel+Carboplatin","description":"Necitumumab 800 milligram (mg) administered intravenously (IV) on Days 1 and 8 of every 3 week cycle.\n\nPaclitaxel 200 milligram per square meter (mg/m²) administered IV on Day 1 of every 3 week cycle.\n\nCarboplatin AUC6 administered IV on Day 1 of every 3 week cycle. The combination of paclitaxel-carboplatin and necitumumab may continue for a maximum of 6 cycles."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"92"}]}],"classes":[{"title":"Cycle 1, Day 1 (n=92)","categories":[{"measurements":[{"groupId":"OG000","value":"262.418","spread":"32.84"}]}]},{"title":"Cycle 3, Day 1 (n=72)","categories":[{"measurements":[{"groupId":"OG000","value":"296.843","spread":"62.97"}]}]},{"title":"Cycle 5, Day 1 (n=62)","categories":[{"measurements":[{"groupId":"OG000","value":"303.475","spread":"53.75"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Anti Necitumumab Antibodies","populationDescription":"All participants who received any amount of necitumumab and had post baseline antibody data.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Baseline to End of Cycle 6","groups":[{"id":"OG000","title":"Necitumumab + Paclitaxel+ Carboplatin","description":"Necitumumab 800 milligram (mg) administered intravenously (IV) on Days 1 and 8 of every 3 week cycle.\n\nPaclitaxel 200 milligram per square meter (mg/m²) administered IV on Day 1 of every 3 week cycle.\n\nCarboplatin AUC6 administered IV on Day 1 of every 3 week cycle."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"106"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8"}]}]}]},{"type":"SECONDARY","title":"Progression-Free Survival","description":"Progression-Free Survival (PFS) is defined as the time from randomization until the first radiographically documented progressive disease (PD) or death from any cause. PD defined by Response Evaluation Criteria in Solid Tumors Criteria (RECIST version 1.1) as at least a 20% increase in the sum of the diameters of target lesions,taking as reference the smallest sum on study (including the baseline sum if that is the smallest). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression. For participants not known to have died as of the data cut-off date and who do not have objective PD, PFS will be censored at the date of the last complete radiographic assessment.","populationDescription":"All randomized participants; with 15 and 7 censored participants in Paclitaxel +Carboplatin + Necitumumab and Paclitaxel +Carboplatin Arms, respectively.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Randomization to Progressive Disease or Death (Up to 24 Months)","groups":[{"id":"OG000","title":"Necitumumab +Paclitaxel+Carboplatin","description":"Necitumumab 800 milligram (mg) administered intravenously (IV) on Days 1 and 8 of every 3 week cycle.\n\nPaclitaxel 200 milligram per square meter (mg/m²) administered IV on Day 1 of every 3 week cycle.\n\nCarboplatin AUC6 administered IV on Day 1 of every 3 week cycle."},{"id":"OG001","title":"Paclitaxel + Carboplatin","description":"Paclitaxel 200 mg/m² administered IV on Day 1 of every 3 week cycle. Carboplatin AUC6 administered IV on Day 1 of every 3 week cycle."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"110"},{"groupId":"OG001","value":"57"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.4","lowerLimit":"4.2","upperLimit":"5.7"},{"groupId":"OG001","value":"5.6","lowerLimit":"4.3","upperLimit":"6.8"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieve Best Overall Disease Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD) (Disease Control Rate [DCR])","description":"Defined using the same denominator as defined in ORR. Among participants counted in the denominator, the numerator counts those with a confirmed best tumor response of SD, PR, or CR per RECIST 1.1. (SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD; PR at least 30% decrease in the sum of diameter of target lesions; CR: disappearance of all target lesions).","populationDescription":"All randomized participants who received at least 1 dose of study drug and who had a complete radiographic assessment.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Baseline to Progressive Disease and/or Death (Estimated up to 24 Months)","groups":[{"id":"OG000","title":"Necitumumab +Paclitaxel+Carboplatin","description":"Necitumumab 800 milligram (mg) administered intravenously (IV) on Days 1 and 8 of every 3 week cycle.\n\nPaclitaxel 200 milligram per square meter (mg/m²) administered IV on Day 1 of every 3 week cycle.\n\nCarboplatin AUC6 administered IV on Day 1 of every 3 week cycle."},{"id":"OG001","title":"Paclitaxel + Carboplatin","description":"Paclitaxel 200 mg/m² administered IV on Day 1 of every 3 week cycle. Carboplatin AUC6 administered IV on Day 1 of every 3 week cycle."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"50"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87.2","lowerLimit":"78.8","upperLimit":"93.2"},{"groupId":"OG001","value":"84.0","lowerLimit":"70.9","upperLimit":"92.8"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Tumor Size (CTS)","description":"CTS is defined as maximum percent change from baseline in the sum of target lesions.","populationDescription":"All randomized participants who received at least 1 dose of study drug and who had a decrease from baseline in the sum of target lesions.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"percent change in tumor size","timeFrame":"Baseline to Progressive Disease or Death (Up to 24 Months)","groups":[{"id":"OG000","title":"Necitumumab +Paclitaxel+Carboplatin","description":"Necitumumab 800 milligram (mg) administered intravenously (IV) on Days 1 and 8 of every 3 week cycle.\n\nPaclitaxel 200 mg per square meter (mg/m²) administered IV on Day 1 of every 3 week cycle.\n\nCarboplatin AUC6 administered IV on Day 1 of every 3 week cycle."},{"id":"OG001","title":"Paclitaxel + Carboplatin","description":"Paclitaxel 200 mg/m² administered IV on Day 1 of every 3 week cycle. Carboplatin AUC6 administered IV on Day 1 of every 3 week cycle."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"83"},{"groupId":"OG001","value":"43"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-44.3","spread":"22.8"},{"groupId":"OG001","value":"-38.65","spread":"24.4"}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetics (PK): Minimum Concentration (Cmin) of Necitumumab","populationDescription":"All participants who received at least one dose of study drug and had evaluable PK data.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"nanogram/milliliter (ng/mL)","timeFrame":"Cycle 1, Day 8 ; Cycle 2, Day 1; Cycle 3, Day 1;Cycle 4, Day1;Cycle 5, Day 1; Cycle 6, Day 1 (within 2 hours prior to beginning of infusion)","groups":[{"id":"OG000","title":"Necitumumab +Paclitaxel+Carboplatin","description":"Necitumumab 800 milligram (mg) administered intravenously (IV) on Days 1 and 8 of every 3 week cycle.\n\nPaclitaxel 200 milligram per square meter (mg/m²) administered IV on Day 1 of every 3 week cycle.\n\nCarboplatin AUC6 administered IV on Day 1 of every 3 week cycle."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"92"}]}],"classes":[{"title":"Cycle 1, Day 8 (n-85)","categories":[{"measurements":[{"groupId":"OG000","value":"59.269","spread":"59.06"}]}]},{"title":"Cycle 2, Day 1 (n=79)","categories":[{"measurements":[{"groupId":"OG000","value":"47.874","spread":"79.89"}]}]},{"title":"Cycle 3, Day 1 (n=76)","categories":[{"measurements":[{"groupId":"OG000","value":"78.142","spread":"70.99"}]}]},{"title":"Cycle 4, Day 1 (n=70)","categories":[{"measurements":[{"groupId":"OG000","value":"80.392","spread":"74.42"}]}]},{"title":"Cycle 5, Day 1 (n=62)","categories":[{"measurements":[{"groupId":"OG000","value":"89.137","spread":"88.94"}]}]},{"title":"Cycle 6, Day 1 (n=59)","categories":[{"measurements":[{"groupId":"OG000","value":"87.043","spread":"85.02"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","description":"All participants who received at least 1 dose of study drug.","eventGroups":[{"id":"EG000","title":"Necitumumab +Paclitaxel+Carboplatin","description":"Necitumumab 800 milligram (mg) administered intravenously (IV) on Days 1 and 8 of every 3 week cycle.\n\nPaclitaxel 200 milligram per square meter (mg/m²) administered IV on Day 1 of every 3 week cycle.\n\nCarboplatin AUC6 administered IV on Day 1 of every 3 week cycle. The combination of paclitaxel-carboplatin and necitumumab may continue for a maximum of 6 cycles.","seriousNumAffected":43,"seriousNumAtRisk":106,"otherNumAffected":102,"otherNumAtRisk":106},{"id":"EG001","title":"Paclitaxel + Carboplatin","description":"Paclitaxel 200 mg/m²) administered IV on Day 1 of every 3 week cycle. Carboplatin AUC6 administered IV on Day 1 of every 3 week cycle. The combination of paclitaxel-carboplatin may continue for a maximum of 6 cycles.","seriousNumAffected":21,"seriousNumAtRisk":55,"otherNumAffected":49,"otherNumAtRisk":55}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":106},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":55}]},{"term":"Anaemia of chronic disease","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":106},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":55}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":106},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":55}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":106},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":55}]},{"term":"Cardiac arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Cardiac failure congestive","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Gastric ulcer haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Ileus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Small intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Upper gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":5,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Brain death","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Sudden death","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Systemic inflammatory response syndrome","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Bacterial sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Clostridium difficile colitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Diverticulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Herpes simplex","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Herpes zoster","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Lung infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Perirectal abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":14,"numAtRisk":106},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":55}]},{"term":"Pneumonia bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Pneumonia viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":106},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":55}]},{"term":"Septic shock","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Thermal burn","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":106},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":55}]},{"term":"Hypocalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Malignant neoplasm progression","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Malignant pleural effusion","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Cerebral ischaemia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Depressed level of consciousness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Encephalopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Loss of consciousness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Delirium","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Mental status changes","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Acute respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Bronchial obstruction","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Interstitial lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Pneumothorax spontaneous","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Pulmonary haemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":55}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Circulatory collapse","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Haemorrhage","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Hypovolaemic shock","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":55}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":87,"numAffected":34,"numAtRisk":106},{"groupId":"EG001","numEvents":62,"numAffected":27,"numAtRisk":55}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":9,"numAtRisk":106},{"groupId":"EG001","numEvents":15,"numAffected":9,"numAtRisk":55}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":73,"numAffected":37,"numAtRisk":106},{"groupId":"EG001","numEvents":43,"numAffected":16,"numAtRisk":55}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":67,"numAffected":27,"numAtRisk":106},{"groupId":"EG001","numEvents":31,"numAffected":14,"numAtRisk":55}]},{"term":"Vision blurred","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":106},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":55}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":8,"numAtRisk":106},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":55}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":28,"numAffected":25,"numAtRisk":106},{"groupId":"EG001","numEvents":23,"numAffected":15,"numAtRisk":55}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":34,"numAffected":26,"numAtRisk":106},{"groupId":"EG001","numEvents":18,"numAffected":12,"numAtRisk":55}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":106},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":55}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":35,"numAffected":27,"numAtRisk":106},{"groupId":"EG001","numEvents":34,"numAffected":20,"numAtRisk":55}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":14,"numAtRisk":106},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":55}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":13,"numAtRisk":106},{"groupId":"EG001","numEvents":11,"numAffected":8,"numAtRisk":55}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":31,"numAffected":18,"numAtRisk":106},{"groupId":"EG001","numEvents":5,"numAffected":3,"numAtRisk":55}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":52,"numAffected":33,"numAtRisk":106},{"groupId":"EG001","numEvents":48,"numAffected":24,"numAtRisk":55}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":11,"numAtRisk":106},{"groupId":"EG001","numEvents":9,"numAffected":7,"numAtRisk":55}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":7,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":10,"numAtRisk":106},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":55}]},{"term":"Conjunctivitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":7,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Paronychia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":6,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":6,"numAtRisk":106},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":55}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":106},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":55}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":7,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":8,"numAtRisk":106},{"groupId":"EG001","numEvents":7,"numAffected":6,"numAtRisk":55}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":49,"numAffected":31,"numAtRisk":106},{"groupId":"EG001","numEvents":20,"numAffected":14,"numAtRisk":55}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":40,"numAffected":34,"numAtRisk":106},{"groupId":"EG001","numEvents":20,"numAffected":15,"numAtRisk":55}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":11,"numAtRisk":106},{"groupId":"EG001","numEvents":17,"numAffected":10,"numAtRisk":55}]},{"term":"Hypoalbuminaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":5,"numAtRisk":106},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":55}]},{"term":"Hypocalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":10,"numAtRisk":106},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":55}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":28,"numAffected":14,"numAtRisk":106},{"groupId":"EG001","numEvents":7,"numAffected":4,"numAtRisk":55}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":74,"numAffected":25,"numAtRisk":106},{"groupId":"EG001","numEvents":12,"numAffected":7,"numAtRisk":55}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":7,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":61,"numAffected":24,"numAtRisk":106},{"groupId":"EG001","numEvents":29,"numAffected":13,"numAtRisk":55}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":10,"numAtRisk":106},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":55}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":8,"numAtRisk":106},{"groupId":"EG001","numEvents":14,"numAffected":8,"numAtRisk":55}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":10,"numAtRisk":106},{"groupId":"EG001","numEvents":7,"numAffected":4,"numAtRisk":55}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":9,"numAffected":7,"numAtRisk":55}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":3,"numAtRisk":106},{"groupId":"EG001","numEvents":7,"numAffected":4,"numAtRisk":55}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":44,"numAffected":18,"numAtRisk":106},{"groupId":"EG001","numEvents":21,"numAffected":12,"numAtRisk":55}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":8,"numAtRisk":106},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":55}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":14,"numAtRisk":106},{"groupId":"EG001","numEvents":10,"numAffected":8,"numAtRisk":55}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":8,"numAtRisk":106},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":55}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":4,"numAtRisk":106},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":55}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":21,"numAffected":13,"numAtRisk":106},{"groupId":"EG001","numEvents":18,"numAffected":9,"numAtRisk":55}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":106},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":55}]},{"term":"Peripheral sensory neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":54,"numAffected":31,"numAtRisk":106},{"groupId":"EG001","numEvents":24,"numAffected":13,"numAtRisk":55}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":14,"numAtRisk":106},{"groupId":"EG001","numEvents":7,"numAffected":6,"numAtRisk":55}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":24,"numAffected":18,"numAtRisk":106},{"groupId":"EG001","numEvents":10,"numAffected":10,"numAtRisk":55}]},{"term":"Dysphonia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":106},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":55}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":29,"numAffected":23,"numAtRisk":106},{"groupId":"EG001","numEvents":13,"numAffected":6,"numAtRisk":55}]},{"term":"Dyspnoea exertional","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":55}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":106},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":55}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":106},{"groupId":"EG001","numEvents":8,"numAffected":6,"numAtRisk":55}]},{"term":"Nasal congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":4,"numAtRisk":106},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":55}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":106},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":55}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":55}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":30,"numAffected":28,"numAtRisk":106},{"groupId":"EG001","numEvents":11,"numAffected":10,"numAtRisk":55}]},{"term":"Dermatitis acneiform","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":40,"numAffected":23,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":13,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":69,"numAffected":22,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":55}]},{"term":"Rash maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":8,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Rash papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":12,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":55}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":12,"numAtRisk":106},{"groupId":"EG001","numEvents":10,"numAffected":7,"numAtRisk":55}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"pointOfContact":{"title":"Chief Medical Officer","organization":"Eli Lilly and Company","phone":"800-545-5979"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17","removedCountries":["Hungary"]},"interventionBrowseModule":{"meshes":[{"id":"C527969","term":"necitumumab"},{"id":"D017239","term":"Paclitaxel"},{"id":"D016190","term":"Carboplatin"}],"ancestors":[{"id":"D043823","term":"Taxoids"},{"id":"D043822","term":"Cyclodecanes"},{"id":"D003516","term":"Cycloparaffins"},{"id":"D006840","term":"Hydrocarbons, Alicyclic"},{"id":"D006844","term":"Hydrocarbons, Cyclic"},{"id":"D006838","term":"Hydrocarbons"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D004224","term":"Diterpenes"},{"id":"D013729","term":"Terpenes"},{"id":"D056831","term":"Coordination Complexes"}]}},"hasResults":true}